Choreograph / iStockphoto.com
Novartis has finalised its agreement with biopharmaceutical company Ionis Pharmaceuticals and its wholly-owned subsidiary Akcea Therapeutics to develop and commercialise therapies for cardiovascular disorders.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Novartis, Ionis Pharmaceuticals, Akcea Therapeutics, cardiovascular disorders, agreement,